Efficacy Study of Canakinumab to Treat Urticaria

Summary

Evaluation whether canakinumab leads to improvement of urticaria

Timeline

Start

2012-06

Primary completion

2016-12

Completion

2017-05

Outcome

Missed primary endpoint

paper failed the significant superiority to the placebo (P = 1.0). PMID 32827729 ↗

Publications

• Maul JT, Distler M, Kolios A, Maul LV, Guillet C, Graf N, Imhof L, Lang C, Navarini AA, Schmid-Grendelmeier P. Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. J Allergy Clin Immunol Pract. 2021 Jan;9(1):463-468.e3. doi: 10.1016/j.jaip.2020.07.058. Epub 2020 Aug 20.

Drugs

Indications